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Abstract 
Although several clinicopathological studies
of  malignant  melanoma  of  the  nasal  cavity
have been reported, there are no studies of the
expression  and  gene  mutation  of  KIT  and
platelet  derived  growth  factor  receptor-α
(PDGFRA) in melanoma of the nasal cavity. A
92-year-old Japanese woman consulted to our
hospital because of right nasal obstruction and
epistaxis. Physical examination and imaging
modalities showed a tumor of the right nasal
cavity.  A  biopsy  was  taken,  and  it  showed
malignant epithelioid cells with melanin depo-
sition. Immunohistochemically, the tumor was
positive for S100 protein, HMB45, p53, Ki-67
(labeling=20%), KIT and PDGFRA. The tumor
was  negative  for  cytokeratins  (AE1/3  and
CAM5.2). A genetic analysis using PCR-direct
sequencing revealed no mutation of KIT gene
(exons 9, 11, 13, and 17) or the PDGFRA gene
(exons 12 and 18). The pathological diagnosis
was primary malignant melanoma of the nasal
cavity. The tumor was reduced in size by local
resection and chemotherapy (Darthmose regi-
men: dacarbazine, carmustine, cisplatine, and
tamoxifen), and the patient is now alive and
free from metastasis 9 months after the first
manifestation.  In  conclusion,  the  author
reported a case of melanoma of the nasal cavi-
ty expressing KIT and PDGFRA without gene
mutations of KIT and PDGFRA. 
Introduction
Malignant melanoma is a highly malignant
tumor,  and  NRAS and  BRAF mutations  are
mainly  involved  in  the  pathogenesis  of
melanoma.1,2 KIT gene,  mapped  to  4q12,
encodes  an  oncogenic  transmembranous
receptor tyrosine kinase, KIT, whose ligand is
stem cell factor.3 The platelet derived growth
factor receptor-α (PDGFRA) gene, also mapped
to 4q12, also encodes an oncogenic transmem-
branous  receptor  tyrosine  kinase,  PDGFRA.3
The KIT gene plays an important role in the
melanocyte migration, development, differen-
tiation  and  tumorigenesis.4 Previous  studies
have shown that activating mutations of the
KIT gene may lead to tumorigenesis of cuta-
neous  melanoma.1 Since  KIT and  PDGFRA
genes  are  mapped  to  4q12,  it  is  anticipated
that PDGFRA gene mutations are involved in
the tumorigenesis of melanoma, as in the case
of gastrointestinal stromal tumors.3 However,
PDGFRA gene  mutations  in  melanoma  have
rarely been examined.5-8 In addition, PDGFRA
protein expression has rarely been analyzed in
melanoma.  These  studies  have  been  per-
formed in Caucasians, and only two reports by
Ashida  et  al.6 and  ours7 are  available  in
Mongoloids,  including  Japanese,  in  which
malignant  melanoma  is  much  more  uncom-
mon than in Caucasians. Ashida et al.6 report-
ed  that  KIT  protein  expression  was  48%  in
Japanese cutaneous melanoma and that KIT
mutation  was  16%  in  Japanese  cutaneous
melanoma. Our previous study7has shown that
KIT and  PDGFRA expression  in  cutaneous
melanoma  was  present  in  92%  and  100%,
respectively,  and  that  mutations  of  KIT and
PDGFRA were  recognized  in  8%  and  0%,
respectively, in cutaneous melanoma.
Although several clinicopathological studies
on melanoma of the nasal cavity have been
performed9,10there have been no studies of KIT
and PDGFRA in melanoma of the nasal cavity.
In the present study, the author investigated
the protein expression and gene mutation sta-
tus  of  KIT  and  PDGFRA in  a  case  of  nasal
melanoma of a Japanese woman. 
Case Report 
A 92-year-old Japanese woman consulted to
our hospital because of right nasal obstruction
and epistaxis. Physical examination revealed a
black tumor measuring of the right nasal cavi-
ty. Imaging modalities also showed a tumor in
the right nasal cavity (Figure 1). A biopsy was
taken,  and  the  biopsy  showed  malignant
epithelioid cells with brown pigment deposi-
tion (Figure 2). The brown pigment was posi-
tive with Fontana-Masson stain, and thought
to be melanin. 
An immunohistochemical analysis was per-
formed, using Dako’s Envision method, as pre-
viously described.11-13 Immunohisto  chemically,
the tumor cells were positive for S100 protein
(Figure  3),  HMB45  (Figure  4),  p53,  Ki-67
(labeling=20%), KIT (Figure 5) and PDGFRA
(Figure 6). The tumor was negative for cytok-
eratins (AE1/3 and CAM5.2).
Genetic analyses of the KIT gene (exons 9,
11, 13, and 17) and the PDGFRA (exons 12 and
18) gene were performed by the PCR direct
sequencing method, as previously reported.13-17
The exons of both genes were selected because
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Figure 1. Computed tomography demon-
strate obstructing tumor in the right nasal
cavity: A) frontal section; B) coronal sec-
tion.
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they are frequent mutation sites.3 The primers
are shown in Table 1. In brief, genomic DNA
was extracted from paraffin blocks with pro-
teinase  K  digestion  and  phenol/chloroform
extraction, and subjected to PCR for 40 cycles
(94ﾰC for one minute, 52℃ for one minute,
72ﾰC for one minute), using a thermal cycler
(GeneAmp  PCR  system  9700,  Applied
Biosystems, ABI, CA). The annealing tempera-
ture was 53℃. PCR products were extracted,
and subjected to a computed automatic DNA
sequencer (ABI PRISM 3100 Genetic Analyzer,
Applied  Biosystems,  ABI,  CA).  These  tech-
niques revealed that there were no mutations
of the KIT gene (exons 9, 11, 13, and 17) or
PDGFRA gene (exons 12 and 18) in this tumor.
The  pathological  diagnosis  was  primary
nasal melanoma. The tumor was resected as
far as possible by operation. The tumor was
reduced  in  size  by  the  operation  and
chemotherapy  (Darthmose  regimen:  dacar-
bazine,  carmustine,  cisplatine,  and  tamox-
ifen).  Five  courses  of  Dartmouth  regimen
were performed. Extensive operation, lymph
node dissection and radiation therapy were
not  performed  because  of  the  patient’s  old
age (92 years). The patient is now alive free
from metastasis 9 months after the first man-
ifestation.
Discussion 
The present study is the second report of
PDGFRAprotein status in melanoma and is the
first in melanoma of the nasal cavity. Our pre-
vious  study7 showed  100%  expression  of
PDGFRA protein in cutaneous melanoma. The
present study is the forth report of PDGFRA
mutations in melanoma; the first was reported
by  Curtin  et  al.,5 who  found  no  PDGFRA
mutations  in  26  cutaneous  melanomas.  The
second  was  reported  by  Sihto  et  al.,18 who
demonstrated no PDGFRA gene mutations in
14  cutaneous  melanomas.  The  third  was
reported by us; no mutations of PDGFRA gene
were found in 12 cutaneous melanoma. The
present case is the first report of PDGFRAgene
status  in  the  nasal  melanoma.  The  present
case  suggests  that  PDGFRA protein  is
expressed  in  nasal  melanoma,  but  PDGFRA
gene mutation is absent in nasal melanoma. 
The present case showed no mutations of
the KIT gene. Studies of KIT mutations are
scant in number in cutaneous melanoma, and
there are none in nasal melanoma. Willmore-
Payne et al.19 showed only 2% of melanomas
had KIT mutations. Sihto et al.18 showed no
KIT mutation in 14 cutaneous melanomas. In
contrast, Curtin et al.1 showed that KIT muta-
tions  are  present  in  39%  of  mucosal
melanomas, in 36% of acral melanomas, 28%
in melanomas of sun-damaged skin, and in 0%
of  melanomas  of  non-sun-damaged  skin.
Beadling  et  al.20 recently  reported  that  KIT
mutations  were  present  in  23%  of  acral
melanomas,  15.6%  of  mucosal  melanomas,
1.7% of cutaneous melanomas, 7.7% of con-
junctival  melanomas,  and  0%  of  choroidal
melanomas.  Handolias  et  al.21 reported  that
KIT mutation was present in 2% of melanomas
and that KIT mutation is frequent in acral and
sun-damaged  skin  melanomas  and  mucosal
melanomas while it was very rare in non-sun-
damaged skin melanoma. In the present case,
Case Report
Figure  2.  Histology  of  the  conjunctival
tumor. Malignant epitheloid cells are seen.
Brown  pigment  was  present.  These  fea-
tures  are  suspicious  of  conjunctival
melanoma. Hematoxyne and Eosine x200.
Figure 3.  The tumor cells are positive for
S100 protein. Immunostaining x200.
Figure 4.  The tumor cells are positive for
HMB45. Immunostaining, x200.
Figure 5.  The tumor cells are positive for
KIT protein. Immunostaining, x200.
Figure 6.  The tumor cells are positive for
PDGFRA. Immunostaining, x200.
Table 1. Primer sequence 
Forward Reverse
KIT exon 9    
5’-TCC TAG AGT AAG CCA GGG CTT-3’ 5’-TGG TAG ACA GAG CCT AAA CAT CC-3’
KIT exon11 
5’-GAT CTA TTT TTC CCT TTC TC-3’ 5’AGC CCC TGT TTC ATA CTG AC-3’
KIT exon 13 
5’-GCT TGA CAT CAG TTT GCC AG -3’ 5’-AAA GGC AGC TTG GAC ACG GCT TTA-3’
KIT exon 17 
5’-CTC CTC CAA CCT AAT AGT GT-3’ 5’-GTC AAG CAG AGA ATG GGT AC-3’
PDGFRA exon12 
5’-TTG GAT ATT CAC CAG TTA CCT GTC-3’ 5’-CAA GGG AAA AGC TCT TGG-3’
PDGFRAexon 18 
5’-ACC ATG GAT CAG CCA GTC TT-3’ 5’-TGA AGG AGG ATG AGC CTG ACC-3’[page 168] [Rare Tumors 2011; 3:e54]
no mutations were seen in the KITgene. Since
KIT mutational  studies  are  scant  in  nasal
melanoma,  more  studies  remain  to  be  per-
formed.
The present case showed positive KIT pro-
tein expression in nasal melanoma. The per-
centage  of  KIT  expression  in  cutaneous
melanomas varies among researchers. There
have  been  no  reports  of  KIT  expression  in
nasal melanoma, to the best of our knowledge.
The percentage in the literature ranges from
21%22 to 84%.23 Sihto et al.18 reported that KIT
expression  in  most  human  solid  tumors,
including melanomas, were due to KIT gene
amplification. More studies of the relationship
between KIT gene mutations and KIT protein
expression in nasal melanoma remain to be
performed.    
In conclusion, the author reported a case of
melanoma of the nasal cavity expressing KIT
and PDGFRA proteins without gene mutations
of KIT and PDGFRA.
References 
1. Curtin JA, Busam K, Pinkel D, Bastian BC.
Somatic activation of KIT in distinct sub-
types  of  melanoma.  J  Clin  Oncol
2006;24:4340-6. 
2. Curtin JA, Fridlyand J, Kageshita T, et al.
Distinct  sets  of  genetic  alterations  in
melanoma. N Engl J Med 2005;353:2135-
47.
3. Hirota S, Isozaki K. Pathology of gastroin-
testinal  stromal  tumor.  Pathol  Int
2006;56:1-9. 
4. Alexeev V, Yoon K. Distinctive role of c-Kit
receptor  tyrosine  kinase  signaling  in
mammalian  melanocytes.  J  Invest
Dermatol 2006;126:1102-10.
5. Curtin JA, Pinkel D, Bastian BC. Absence
of  PDGFRA  mutations  in  primary
melanoma.  J  Invest  Dermatol
2008;128:488-9.
6. Ashida  A,  Takata  M,  Murata  H,  et  al.
Pathological activation of KIT in metastat-
ic  tumors  of  acral  and  mucosal
melanomas. Int J Cancer 2009;124:862-8.
7. Terada T. Low incidence of KIT gene muta-
tions and no PDGFRA gene mutations in
primary  cutaneous  melanoma:  an
immunohistochemical  and  molecular
genetic study of Japanese cases. Int J Clin
Oncol 2010;15;453-6.
8. Terada T. Amelanotic malignant melanoma
of the esophagus: report of two cases with
immunohistocheimcal  and  molecular
genetic study of KIT and PDGFRA. World J
Gastroenterol 2009;15:2679-83.
9. Clifton N, Harrison L, Gradley PJ, Jones
NS. Malignant melanoma of the nasal cav-
ity  and  paranasal  sinuses:  report  of  24
patients and literature review. J Laryngo
Otol 2011;125:479-85.
10. Dauer EH, Lewis JE, Rholinger AL, et al.
Sinonasal melanoma: a clonicopathologic
review of 61 cases. Otolaryngol Head Neck
Surg 2008;138:347-52. 
11. Terada T, Kawaguchi M, Furukawa K, et al.
Minute mixed ductal-endocrine carcinoma
of the pancreas with predominant intra-
ductal growth. Pathol Int  2002;52:740-6.
12. Terada T, Tanigichi M. Intraductal oncocyt-
ic papillary neoplasm of the liver. Pathol
Int 2004;54:116-23.
13. Terada T. Gastrointestinal stromal tumor
of the uterus: a case report with genetic
analyses of c-kit and PDGFRA genes. Int J
Gynecol Oncol 2009;28:29-34.
14. Terada T. Mediastinal seminoma with mul-
tiple  KIT  gene  mutations.  Pathology
2009;41:695-7. 
15. Terada T. Mutations and protein expres-
sion of KIT and PDGFRA genes in ipsilater-
al testicular seminomas: an immunohisto-
chemical  and  molecular  genetic  study.
Appl  Immunohistochem  Mol  Morphol
[Epub ahead of print]
16. Terada  T.  Primary  extragastrointestinal
stromal  tumors  of  the  transverse  meso-
colon  without  c-kit  mutations  but  with
PDGFRA  mutations.  Med  Oncol  2009;26:
233-7.  
17. Terada T. Primary multiple extragastroin-
testinal stromal tumors of the omentum
with  different  mutations  of  c-kit  gene.
World J Gastroenterol 2008;14:7256-9.
18. Sihto H, Sarlomo-Rikara M, Tynnienen O,
et al. KIT and platelet-derived growth fac-
tor  receptor  alpha  tyrosine  kinase  gene
mutations  and  KIT  amplifications  in
human solid tumors. J Clin Oncol 2005;23:
49-57.
19. Willmore-Payne  C,  Holden  JA,  Tripps  S,
Layfield  LJ. Human malignant melanoma:
detection  of  BRAF-  and  c-kit-activating
mutations  by  high-resolution  amplicon
melting analysis. Hum Pathol 2005;36:486-
93.
20. Beadling C, Jacobson-Dunlop E, Hodi FS,
et al. KIT gene mutation and copy number
in  melanoma  subtypes.  Clin  Cancer  Res
2008;14:6821-8.
21. Handlias  D,  Salemi  R,  Murray  W,  et  al.
Mutations in KIT occur at low frequency in
melanomas arising from anatomical sites
associated with chronic and intermittent
sun exposure. Pigment Cell Melanoma Res
2010. [Epub ahead of print]
22. Arber DA, Tamaya R, Weiss LM. Paraffin
section detection of the c-kit gene product
(CD117) in human tissues: value in the
diagnosis  of  mast  cell  disorders.  Hum
Pathol 1998;29:498-504.
23. Montone KT, van Belle P, Elenitsas R, Elder
DE.  Proto-oncogene  c-kit  in  malignant
melanoma:  protein  loss  with  tumor  pro-
gression. Mod Pathol 1997;10:939-44.
Case Report